Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) traded down 49.5% during mid-day trading on Wednesday . The stock traded as low as $2.02 and last traded at $2.02. 400 shares traded hands during mid-day trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Stock Down 49.5 %
The business has a 50 day moving average price of $2.02 and a 200 day moving average price of $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Stories
- Five stocks we like better than H-CYTE
- Top Stocks Investing in 5G Technology
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Transportation Stocks Investing
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
